WTA
RARE icon

Washington Trust Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Washington Trust Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79
Closed -$2.89K – 710
2025
Q2 		$2.89K Buy
79
+71
+888% +$2.56K ﹤0.01% 594
2025
Q1 		$290 Sell
8
-49
-86% -$2.04K ﹤0.01% 637
2024
Q4 		$2.4K Hold
57
– – ﹤0.01% 611
2024
Q3 		$3.16K Buy
+57
New +$2.9K ﹤0.01% 615

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Washington Trust Advisors's RARE Position: Q3 2025 in Review

Washington Trust Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 79 shares — an estimated $2.89K sold.

Washington Trust Advisors first reported a position in RARE in Q3 2024 and held it in 4 quarters. The position peaked at $3.16K in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Washington Trust Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 79 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $2.89K.
  • Washington Trust Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 4 quarters.
  • Washington Trust Advisors's Ultragenyx Pharmaceutical position peaked at $3.16K in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Washington Trust Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.